Loading…

The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer

•Different driver mutations have different propensity to develop lymph node metastasis.•Patients with fusion mutations have a higher risk of lymph node metastasis than other mutations.•Patients with fusion mutations present more vascular invasion compared to other mutations. To investigate the incid...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-08, Vol.134, p.218-224
Main Authors: Liu, Zhichao, Liang, Hengrui, Lin, Jie, Cai, Xiuyu, Pan, Zhenkui, Liu, Jun, Xie, Xiaohong, Li, Caichen, Cheng, Bo, Zhao, Yi, He, Jianxing, Liang, Wenhua
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Different driver mutations have different propensity to develop lymph node metastasis.•Patients with fusion mutations have a higher risk of lymph node metastasis than other mutations.•Patients with fusion mutations present more vascular invasion compared to other mutations. To investigate the incidence and distribution of lymph node metastasis in patients with different gene mutations among pathological T1 non-small-cell lung cancers (NSCLC). NSCLC cases resected in our institution between 2016 and 2018 were included. Driver mutation testing was performed in all resected tumor tissues. These patients were grouped by the type of gene mutations. On the basis of protein that mutant-genes encoded involved in the molecular pathway, the genotypes were further classified into four distinct groups: upstream receptor mutant protein (EGFR, HER2 and MET); downstream regulator mutant protein (KRAS and BRAF); fusion mutant protein (ROS1, ALK and RET) and the wild type group. The incidence of lymph node metastasis was compared among different groups. Of the 1052 patients enrolled, the frequency of positive mutations was 68.0%. The incidence of lymph node metastasis were as follows: wild type (19.3%), ROS1 (72.8%), BRAF (55.5%), ALK (44.7%), HER2 (40%), RET (23.1%), KRAS (15.3%), EGFR (15.3%) and MET mutation (0%) (P 
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2019.06.026